{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T14:22:53Z","timestamp":1795184573138,"version":"4.10.3"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Gaucher disease (GD) is a rare, inherited, autosomal recessive disorder caused by a deficiency of the lysosomal enzyme, acid \u03b2-glucosidase. Its diagnosis is achieved via measurements of acid \u03b2-glucosidase activity in either fresh peripheral blood leukocytes or dried blood spots, and confirmed by identifying characteristic mutations in the\n                      <jats:italic>GBA1<\/jats:italic>\n                      gene. Currently, several biomarkers are available for disease monitoring. Chitotriosidase has been used over the last 20\u00a0years to assess the severity of GD, but lacks specificity in GD patients. Conversely, the deacylated form of glucosylceramide, glucosylsphingosine (also known as lyso-Gb1), represents a more reliable biomarker characterized by its high sensitivity and specificity in GD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main text<\/jats:title>\n                    <jats:p>Herein, we review the current literature on lyso-Gb1 and describe evidence supporting its usefulness as a biomarker for diagnosing and evaluating disease severity in GD and monitoring treatment efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Lyso-Gb1 is the most promising biomarker of GD, as demonstrated by its reliability in reflecting disease burden and monitoring treatment response. Furthermore, lyso-Gb1 may play an important role in the onset of monoclonal gammopathy of uncertain significance, multiple myeloma, and Parkinson\u2019s disease in GD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-023-02623-7","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T15:02:46Z","timestamp":1676300566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4947-3338","authenticated-orcid":false,"given":"Gaetano","family":"Giuffrida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uros","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Condorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Calafiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Nicolosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Calagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Tindaro Valentino","family":"Ragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariasanta","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"issue":"4","key":"2623_CR1","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1177\/106002809603000411","volume":"30","author":"LE Morales","year":"1996","unstructured":"Morales LE. Gaucher\u2019s disease: a review. Ann Pharmacother. 1996;30(4):381\u20138.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"2623_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ijns5020024","volume":"5","author":"AB Burlina","year":"2019","unstructured":"Burlina AB, Polo G, Rubert L, Gueraldi D, Cazzorla C, Duro G, et al. Implementation of second-tier tests in newborn screening for lysosomal disorders in North Eastern Italy. Int J Neonatal Screen. 2019;5(2):24.","journal-title":"Int J Neonatal Screen"},{"issue":"5","key":"2623_CR3","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/jimd.12235","volume":"43","author":"R Schiffmann","year":"2020","unstructured":"Schiffmann R, Sevigny J, Rolfs A, Davies EH, Goker-Alpan O, Abdelwahab M, et al. The definition of neuronopathic Gaucher disease. J Inherit Metab Dis. 2020;43(5):1056\u20139.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"2623_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1067\/S0022-3476(03)00302-0","volume":"143","author":"O Goker-Alpan","year":"2003","unstructured":"Goker-Alpan O, Schiffmann R, Park JK, Stubblefield BK, Tayebi N, Sidransky E. Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3. J Pediatr. 2003;143(2):273\u20136.","journal-title":"J Pediatr"},{"key":"2623_CR5","first-page":"177","volume":"95","author":"RE Lee","year":"1982","unstructured":"Lee RE. The pathology of Gaucher disease. Prog Clin Biol Res. 1982;95:177\u2013217.","journal-title":"Prog Clin Biol Res"},{"issue":"12","key":"2623_CR6","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s12325-014-0174-0","volume":"31","author":"G Giuffrida","year":"2014","unstructured":"Giuffrida G, Cappellini MD, Carubbi F, Di Rocco M, Iolascon G. Management of bone disease in Gaucher disease type 1: clinical practice. Adv Ther. 2014;31(12):1197\u2013212.","journal-title":"Adv Ther"},{"key":"2623_CR7","first-page":"CD010324","volume":"3","author":"E Shemesh","year":"2015","unstructured":"Shemesh E, Deroma L, Bembi B, Deegan P, Hollak C, Weinreb NJ, et al. Enzyme replacement and substrate reduction therapy for Gaucher disease. Cochrane Database Syst Rev. 2015;3:CD010324.","journal-title":"Cochrane Database Syst Rev"},{"key":"2623_CR8","unstructured":"European Medicines Agency. Cerezyme (imiglucerase). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cerezyme. Accessed 20 Dec 2021."},{"issue":"1","key":"2623_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","volume":"122","author":"GA Grabowski","year":"1995","unstructured":"Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med. 1995;122(1):33\u20139.","journal-title":"Ann Intern Med"},{"key":"2623_CR10","unstructured":"European Medicines Agency. Vpriv (velaglucerase alfa). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vpriv. Accessed 20 Dec 2021."},{"issue":"23","key":"2623_CR11","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1182\/blood-2010-02-268649","volume":"115","author":"A Zimran","year":"2010","unstructured":"Zimran A, Altarescu G, Philips M, Attias D, Jmoudiak M, Deeb M, et al. Phase 1\/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood. 2010;115(23):4651\u20136.","journal-title":"Blood"},{"key":"2623_CR12","unstructured":"European Medicines Agency. Elelyso (taliglucerase alfa). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elelyso. Accessed 20 Dec 2021."},{"key":"2623_CR13","unstructured":"European Medicines Agency. Zavesca (miglustat). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zavesca. Accessed 20 Dec 2021."},{"key":"2623_CR14","unstructured":"European Medicines Agency. Cerdelga (eliglustat). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cerdelga. Accessed 20 Dec 2021."},{"issue":"11","key":"2623_CR15","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1080\/14656566.2021.1902989","volume":"22","author":"R Sam","year":"2021","unstructured":"Sam R, Ryan E, Daykin E, Sidransky E. Current and emerging pharmacotherapy for Gaucher disease in pediatric populations. Expert Opin Pharmacother. 2021;22(11):1489\u2013503.","journal-title":"Expert Opin Pharmacother"},{"issue":"4 Suppl 5","key":"2623_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.07.010","volume":"41","author":"NJ Weinreb","year":"2004","unstructured":"Weinreb NJ, Aggio MC, Andersson HC, Andria G, Charrow J, Clarke JT, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol. 2004;41(4 Suppl 5):15\u201322.","journal-title":"Semin Hematol"},{"key":"2623_CR17","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/. Accessed 14 Feb 2022."},{"issue":"19","key":"2623_CR18","doi-asserted-by":"publisher","first-page":"7159","DOI":"10.3390\/ijms21197159","volume":"21","author":"S Revel-Vilk","year":"2020","unstructured":"Revel-Vilk S, Fuller M, Zimran A. Value of glucosylsphingosine (Lyso-Gb1) as a biomarker in Gaucher disease: a systematic literature review. Int J Mol Sci. 2020;21(19):7159.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2623_CR19","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1172\/JCI117084","volume":"93","author":"CE Hollak","year":"1994","unstructured":"Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Investig. 1994;93(3):1288\u201392.","journal-title":"J Clin Investig"},{"issue":"4","key":"2623_CR20","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10545-005-0585-9","volume":"28","author":"A Vellodi","year":"2005","unstructured":"Vellodi A, Foo Y, Cole TJ. Evaluation of three biochemical markers in the monitoring of Gaucher disease. J Inherit Metab Dis. 2005;28(4):585\u201392.","journal-title":"J Inherit Metab Dis"},{"issue":"s447","key":"2623_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/08035320510028094","volume":"94","author":"JMFG Aerts","year":"2005","unstructured":"Aerts JMFG, Hollak CEM, van Breemen M, Maas M, Groener JEM, Boot R. Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases. Acta Paediatr. 2005;94(s447):43\u20136.","journal-title":"Acta Paediatr"},{"issue":"5","key":"2623_CR22","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1159\/000100555","volume":"74","author":"E Bargagli","year":"2007","unstructured":"Bargagli E, Margollicci M, Nikiforakis N, Luddi A, Perrone A, Grosso S, et al. Chitotriosidase activity in the serum of patients with sarcoidosis and pulmonary tuberculosis. Respiration. 2007;74(5):548\u201352.","journal-title":"Respiration"},{"issue":"4","key":"2623_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ajh.10294","volume":"72","author":"R Barone","year":"2003","unstructured":"Barone R, Malaguarnera L, Angius A, Musumeci S. Plasma chitotriosidase activity in patients with beta-thalassemia. Am J Hematol. 2003;72(4):285\u20136.","journal-title":"Am J Hematol"},{"issue":"6","key":"2623_CR24","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/BF02436762","volume":"18","author":"Y Guo","year":"1995","unstructured":"Guo Y, He W, Boer AM, Wevers RA, de Bruijn AM, Groener JE, et al. Elevated plasma chitotriosidase activity in various lysosomal storage disorders. J Inherit Metab Dis. 1995;18(6):717\u201322.","journal-title":"J Inherit Metab Dis"},{"issue":"40","key":"2623_CR25","doi-asserted-by":"publisher","first-page":"25680","DOI":"10.1074\/jbc.273.40.25680","volume":"273","author":"RG Boot","year":"1998","unstructured":"Boot RG, Renkema GH, Verhoek M, Strijland A, Bliek J, de Meulemeester TM, et al. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem. 1998;273(40):25680\u20135.","journal-title":"J Biol Chem"},{"key":"2623_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/8904_2015_442","volume":"23","author":"TD Da Silva-Jose","year":"2015","unstructured":"Da Silva-Jose TD, Juarez-Rendon KJ, Juarez-Osuna JA, Porras-Dorantes A, Valladares-Salgado A, Cruz M, et al. Dup-24 bp in the CHIT1 Gene in Six Mexican Amerindian Populations. JIMD Rep. 2015;23:123\u20137.","journal-title":"JIMD Rep"},{"issue":"18","key":"2623_CR27","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.clinbiochem.2013.09.006","volume":"46","author":"P Irun","year":"2013","unstructured":"Irun P, Alfonso P, Aznarez S, Giraldo P, Pocovi M. Chitotriosidase variants in patients with Gaucher disease. Implications for diagnosis and therapeutic monitoring. Clin Biochem. 2013;46(18):1804\u20137.","journal-title":"Clin Biochem"},{"issue":"3","key":"2623_CR28","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.bcmd.2004.07.005","volume":"33","author":"MR Rodrigues","year":"2004","unstructured":"Rodrigues MR, Sa Miranda MC, Amaral O. Allelic frequency determination of the 24-bp chitotriosidase duplication in the Portuguese population by real-time PCR. Blood Cells Mol Dis. 2004;33(3):362\u20134.","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"2623_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.bcmd.2009.09.005","volume":"44","author":"KL Chang","year":"2010","unstructured":"Chang KL, Hwu WL, Yeh HY, Lee NC, Chien YH. CCL18 as an alternative marker in Gaucher and Niemann-Pick disease with chitotriosidase deficiency. Blood Cells Mol Dis. 2010;44(1):38\u201340.","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"2623_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1182\/blood-2003-05-1612","volume":"103","author":"RG Boot","year":"2004","unstructured":"Boot RG, Verhoek M, de Fost M, Hollak CE, Maas M, Bleijlevens B, et al. Marked elevation of the chemokine CCL18\/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood. 2004;103(1):33\u20139.","journal-title":"Blood"},{"issue":"10","key":"2623_CR31","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.3390\/jcm10102217","volume":"10","author":"M Ivanova","year":"2021","unstructured":"Ivanova M, Dao J, Noll L, Fikry J, Goker-Alpan O. TRAP5b and RANKL\/OPG predict bone pathology in patients with Gaucher disease. J Clin Med. 2021;10(10):2217.","journal-title":"J Clin Med"},{"issue":"7","key":"2623_CR32","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.bbadis.2007.04.002","volume":"1772","author":"MJ van Breemen","year":"2007","unstructured":"van Breemen MJ, de Fost M, Voerman JS, Laman JD, Boot RG, Maas M, et al. Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta. 2007;1772(7):788\u201396.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"2623_CR33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ymgme.2018.02.007","volume":"123","author":"SM Danilov","year":"2018","unstructured":"Danilov SM, Tikhomirova VE, Metzger R, Naperova IA, Bukina TM, Goker-Alpan O, et al. ACE phenotyping in Gaucher disease. Mol Genet Metab. 2018;123(4):501\u201310.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"2623_CR34","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1471-4159.1982.tb07950.x","volume":"39","author":"O Nilsson","year":"1982","unstructured":"Nilsson O, Svennerholm L. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J Neurochem. 1982;39(3):709\u201318.","journal-title":"J Neurochem"},{"issue":"4","key":"2623_CR35","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S1096-7192(02)00117-8","volume":"76","author":"E Orvisky","year":"2002","unstructured":"Orvisky E, Park JK, LaMarca ME, Ginns EI, Martin BM, Tayebi N, et al. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol Genet Metab. 2002;76(4):262\u201370.","journal-title":"Mol Genet Metab"},{"issue":"45","key":"2623_CR36","doi-asserted-by":"publisher","first-page":"19473","DOI":"10.1073\/pnas.1003308107","volume":"107","author":"PK Mistry","year":"2010","unstructured":"Mistry PK, Liu J, Yang M, Nottoli T, McGrath J, Jain D, et al. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci USA. 2010;107(45):19473\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"16","key":"2623_CR37","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","volume":"118","author":"N Dekker","year":"2011","unstructured":"Dekker N, van Dussen L, Hollak CE, Overkleeft H, Scheij S, Ghauharali K, et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood. 2011;118(16):e118\u201327.","journal-title":"Blood"},{"issue":"11","key":"2623_CR38","doi-asserted-by":"publisher","first-page":"e79732","DOI":"10.1371\/journal.pone.0079732","volume":"8","author":"A Rolfs","year":"2013","unstructured":"Rolfs A, Giese AK, Grittner U, Mascher D, Elstein D, Zimran A, et al. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS ONE. 2013;8(11):e79732.","journal-title":"PLoS ONE"},{"issue":"11","key":"2623_CR39","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/ajh.24491","volume":"91","author":"V Murugesan","year":"2016","unstructured":"Murugesan V, Chuang WL, Liu J, Lischuk A, Kacena K, Lin H, et al. Glucosylsphingosine is a key biomarker of Gaucher disease. Am J Hematol. 2016;91(11):1082\u20139.","journal-title":"Am J Hematol"},{"key":"2623_CR40","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.chroma.2017.10.038","volume":"1525","author":"C Chipeaux","year":"2017","unstructured":"Chipeaux C, de Person M, Burguet N, Billette de Villemeur T, Rose C, Belmatoug N, et al. Optimization of ultra-high pressure liquid chromatography\u2014tandem mass spectrometry determination in plasma and red blood cells of four sphingolipids and their evaluation as biomarker candidates of Gaucher\u2019s disease. J Chromatogr A. 2017;1525:116\u201325.","journal-title":"J Chromatogr A"},{"issue":"4","key":"2623_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.ymgme.2018.02.004","volume":"123","author":"A Tylki-Szymanska","year":"2018","unstructured":"Tylki-Szymanska A, Szymanska-Rozek P, Hasinski P, Lugowska A. Plasma chitotriosidase activity versus plasma glucosylsphingosine in wide spectrum of Gaucher disease phenotypes\u2014a statistical insight. Mol Genet Metab. 2018;123(4):495\u2013500.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"2623_CR42","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1515\/cclm-2019-0949","volume":"58","author":"P Irun","year":"2020","unstructured":"Irun P, Cebolla JJ, Lopez de Frutos L, De Castro-Oros I, Roca-Espiau M, Giraldo P. LC-MS\/MS analysis of plasma glucosylsphingosine as a biomarker for diagnosis and follow-up monitoring in Gaucher disease in the Spanish population. Clin Chem Lab Med. 2020;58(5):798\u2013809.","journal-title":"Clin Chem Lab Med"},{"issue":"10","key":"2623_CR43","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.3390\/ijms18102192","volume":"18","author":"J Lukas","year":"2017","unstructured":"Lukas J, Cozma C, Yang F, Kramp G, Meyer A, Nesslauer AM, et al. Glucosylsphingosine causes hematological and visceral changes in mice-evidence for a pathophysiological role in Gaucher disease. Int J Mol Sci. 2017;18(10):2192.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2623_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/ajh.25300","volume":"94","author":"E Lukina","year":"2019","unstructured":"Lukina E, Watman N, Dragosky M, Lau H, Avila Arreguin E, Rosenbaum H, et al. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: final results from the Phase 2 trial. Am J Hematol. 2019;94(1):29\u201338.","journal-title":"Am J Hematol"},{"issue":"9","key":"2623_CR45","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/ajh.26276","volume":"96","author":"PK Mistry","year":"2021","unstructured":"Mistry PK, Lukina E, Ben Turkia H, Shankar SP, Baris Feldman H, Ghosn M, et al. Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: phase 3 ENGAGE trial final results. Am J Hematol. 2021;96(9):1156\u201365.","journal-title":"Am J Hematol"},{"issue":"2","key":"2623_CR46","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.ymgme.2018.12.297","volume":"126","author":"J Peterschmitt","year":"2019","unstructured":"Peterschmitt J, Foster M, Zhang K, Ji A, Cox G. Correlations between glucosylsphingosine (lyso-GL-1) and baseline disease severity as well as response to treatment in two clinical trials of eliglustat in treatment-na\u00efve adults with type 1 Gaucher disease. Mol Genet Metab. 2019;126(2):S117.","journal-title":"Mol Genet Metab"},{"issue":"1\u20132","key":"2623_CR47","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ymgme.2017.08.005","volume":"122","author":"D Elstein","year":"2017","unstructured":"Elstein D, Mellgard B, Dinh Q, Lan L, Qiu Y, Cozma C, et al. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naive and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: data from phase 3 clinical trials. Mol Genet Metab. 2017;122(1\u20132):113\u201320.","journal-title":"Mol Genet Metab"},{"issue":"12","key":"2623_CR48","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.3390\/ijms20123033","volume":"20","author":"N Hurvitz","year":"2019","unstructured":"Hurvitz N, Dinur T, Becker-Cohen M, Cozma C, Hovakimyan M, Oppermann S, et al. Glucosylsphingosine (lyso-Gb1) as a biomarker for monitoring treated and untreated children with Gaucher disease. Int J Mol Sci. 2019;20(12):3033.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2623_CR49","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/jimd.12192","volume":"43","author":"JT Saville","year":"2020","unstructured":"Saville JT, McDermott BK, Chin SJ, Fletcher JM, Fuller M. Expanding the clinical utility of glucosylsphingosine for Gaucher disease. J Inherit Metab Dis. 2020;43(3):558\u201363.","journal-title":"J Inherit Metab Dis"},{"key":"2623_CR50","doi-asserted-by":"publisher","first-page":"100729","DOI":"10.1016\/j.ymgmr.2021.100729","volume":"27","author":"AR Stiles","year":"2021","unstructured":"Stiles AR, Huggins E, Fierro L, Jung SH, Balwani M, Kishnani PS. The role of glucosylsphingosine as an early indicator of disease progression in early symptomatic type 1 Gaucher disease. Mol Genet Metab Rep. 2021;27:100729.","journal-title":"Mol Genet Metab Rep"},{"issue":"13","key":"2623_CR51","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.3390\/ijms21134577","volume":"21","author":"C Cozma","year":"2020","unstructured":"Cozma C, Cullufi P, Kramp G, Hovakimyan M, Velmishi V, Gjikopulli A, et al. Treatment efficiency in Gaucher patients can reliably be monitored by quantification of Lyso-Gb1 concentrations in dried blood spots. Int J Mol Sci. 2020;21(13):4577.","journal-title":"Int J Mol Sci"},{"issue":"17","key":"2623_CR52","doi-asserted-by":"publisher","first-page":"15313","DOI":"10.1074\/jbc.M213128200","volume":"278","author":"S Chandra","year":"2003","unstructured":"Chandra S, Chen X, Rizo J, Jahn R, Sudhof TC. A broken alpha -helix in folded alpha -Synuclein. J Biol Chem. 2003;278(17):15313\u20138.","journal-title":"J Biol Chem"},{"issue":"6645","key":"2623_CR53","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839\u201340.","journal-title":"Nature"},{"issue":"28","key":"2623_CR54","doi-asserted-by":"publisher","first-page":"9364","DOI":"10.1523\/JNEUROSCI.4787-13.2014","volume":"34","author":"KJ Vargas","year":"2014","unstructured":"Vargas KJ, Makani S, Davis T, Westphal CH, Castillo PE, Chandra SS. Synucleins regulate the kinetics of synaptic vesicle endocytosis. J Neurosci. 2014;34(28):9364\u201376.","journal-title":"J Neurosci"},{"issue":"6","key":"2623_CR55","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1001\/jamaneurol.2014.313","volume":"71","author":"RN Alcalay","year":"2014","unstructured":"Alcalay RN, Dinur T, Quinn T, Sakanaka K, Levy O, Waters C, et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol. 2014;71(6):752\u20137.","journal-title":"JAMA Neurol"},{"issue":"17","key":"2623_CR56","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med. 2009;361(17):1651\u201361.","journal-title":"N Engl J Med"},{"issue":"40","key":"2623_CR57","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","volume":"37","author":"YV Taguchi","year":"2017","unstructured":"Taguchi YV, Liu J, Ruan J, Pacheco J, Zhang X, Abbasi J, et al. Glucosylsphingosine promotes alpha-synuclein pathology in mutant GBA-associated Parkinson\u2019s disease. J Neurosci. 2017;37(40):9617\u201331.","journal-title":"J Neurosci"},{"issue":"11","key":"2623_CR58","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/hmg\/ddz030","volume":"28","author":"M Ikuno","year":"2019","unstructured":"Ikuno M, Yamakado H, Akiyama H, Parajuli LK, Taguchi K, Hara J, et al. GBA haploinsufficiency accelerates alpha-synuclein pathology with altered lipid metabolism in a prodromal model of Parkinson\u2019s disease. Hum Mol Genet. 2019;28(11):1894\u2013904.","journal-title":"Hum Mol Genet"},{"key":"2623_CR59","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.nbd.2018.09.015","volume":"121","author":"AL Gundner","year":"2019","unstructured":"Gundner AL, Duran-Pacheco G, Zimmermann S, Ruf I, Moors T, Baumann K, et al. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing alpha-synuclein levels. Neurobiol Dis. 2019;121:205\u201313.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"2623_CR60","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/qjmed\/90.1.19","volume":"90","author":"MJ Allen","year":"1997","unstructured":"Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM. Pro-inflammatory cytokines and the pathogenesis of Gaucher\u2019s disease: increased release of interleukin-6 and interleukin-10. QJM. 1997;90(1):19\u201325.","journal-title":"QJM"},{"issue":"Suppl 2","key":"2623_CR61","first-page":"106","volume":"24","author":"TM Cox","year":"2001","unstructured":"Cox TM. Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metab Dis. 2001;24(Suppl 2):106\u201321 (discussion 87\u20138).","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl 1","key":"2623_CR62","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1002\/ajh.24057","volume":"90","author":"TM Cox","year":"2015","unstructured":"Cox TM, Rosenbloom BE, Barker RA. Gaucher disease and comorbidities: B-cell malignancy and parkinsonism. Am J Hematol. 2015;90(Suppl 1):S25\u20138.","journal-title":"Am J Hematol"},{"issue":"6","key":"2623_CR63","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00277-008-0441-8","volume":"87","author":"M de Fost","year":"2008","unstructured":"de Fost M, Out TA, de Wilde FA, Tjin EP, Pals ST, van Oers MH, et al. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol. 2008;87(6):439\u201349.","journal-title":"Ann Hematol"},{"issue":"3","key":"2623_CR64","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1615\/CritRevOncog.2013006145","volume":"18","author":"PK Mistry","year":"2013","unstructured":"Mistry PK, Taddei T, vom Dahl S, Rosenbloom BE. Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism. Crit Rev Oncog. 2013;18(3):235\u201346.","journal-title":"Crit Rev Oncog"},{"issue":"1","key":"2623_CR65","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/path.4227","volume":"231","author":"EV Pavlova","year":"2013","unstructured":"Pavlova EV, Wang SZ, Archer J, Dekker N, Aerts JM, Karlsson S, et al. B cell lymphoma and myeloma in murine Gaucher\u2019s disease. J Pathol. 2013;231(1):88\u201397.","journal-title":"J Pathol"},{"issue":"1","key":"2623_CR66","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/path.4452","volume":"235","author":"EV Pavlova","year":"2015","unstructured":"Pavlova EV, Archer J, Wang S, Dekker N, Aerts JM, Karlsson S, et al. Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy. J Pathol. 2015;235(1):113\u201324.","journal-title":"J Pathol"},{"issue":"6","key":"2623_CR67","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa1508808","volume":"374","author":"S Nair","year":"2016","unstructured":"Nair S, Branagan AR, Liu J, Boddupalli CS, Mistry PK, Dhodapkar MV. Clonal immunoglobulin against lysolipids in the origin of myeloma. N Engl J Med. 2016;374(6):555\u201361.","journal-title":"N Engl J Med"},{"issue":"4","key":"2623_CR68","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ymgme.2020.01.009","volume":"129","author":"S Nair","year":"2020","unstructured":"Nair S, Bar N, Xu ML, Dhodapkar M, Mistry PK. Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. Mol Genet Metab. 2020;129(4):286\u201391.","journal-title":"Mol Genet Metab"},{"issue":"17","key":"2623_CR69","doi-asserted-by":"publisher","first-page":"9726","DOI":"10.1111\/jcmm.15534","volume":"24","author":"L Dupuis","year":"2020","unstructured":"Dupuis L, Chipeaux C, Bourdelier E, Martino S, Reihani N, Belmatoug N, et al. Effects of sphingolipids overload on red blood cell properties in Gaucher disease. J Cell Mol Med. 2020;24(17):9726\u201336.","journal-title":"J Cell Mol Med"},{"issue":"6","key":"2623_CR70","doi-asserted-by":"publisher","first-page":"E140","DOI":"10.1002\/ajh.25074","volume":"93","author":"D Arkadir","year":"2018","unstructured":"Arkadir D, Dinur T, Revel-Vilk S, Becker Cohen M, Cozma C, Hovakimyan M, et al. Glucosylsphingosine is a reliable response biomarker in Gaucher disease. Am J Hematol. 2018;93(6):E140\u20132.","journal-title":"Am J Hematol"},{"issue":"14","key":"2623_CR71","doi-asserted-by":"publisher","first-page":"7699","DOI":"10.3390\/ijms22147699","volume":"22","author":"T Dinur","year":"2021","unstructured":"Dinur T, Grittner U, Revel-Vilk S, Becker-Cohen M, Istaiti M, Cozma C, et al. Impact of long-term enzyme replacement therapy on glucosylsphingosine (Lyso-Gb1) values in patients with type 1 Gaucher disease: statistical models for comparing three enzymatic formulations. Int J Mol Sci. 2021;22(14):7699.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2623_CR72","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","volume":"91","author":"KA McEachern","year":"2007","unstructured":"McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, Hutto E, et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab. 2007;91(3):259\u201367.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2623_CR73","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13023-019-1085-6","volume":"14","author":"MJ Peterschmitt","year":"2019","unstructured":"Peterschmitt MJ, Freisens S, Underhill LH, Foster MC, Lewis G, Gaemers SJM. Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1. Orphanet J Rare Dis. 2019;14(1):128.","journal-title":"Orphanet J Rare Dis"},{"key":"2623_CR74","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13023-016-0413-3","volume":"11","author":"BE Smid","year":"2016","unstructured":"Smid BE, Ferraz MJ, Verhoek M, Mirzaian M, Wisse P, Overkleeft HS, et al. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients. Orphanet J Rare Dis. 2016;11:28.","journal-title":"Orphanet J Rare Dis"},{"key":"2623_CR75","doi-asserted-by":"publisher","first-page":"100798","DOI":"10.1016\/j.ymgmr.2021.100798","volume":"29","author":"N Kleytman","year":"2021","unstructured":"Kleytman N, Ruan J, Ruan A, Zhang B, Murugesan V, Lin H, et al. Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease. Mol Genet Metab Rep. 2021;29:100798.","journal-title":"Mol Genet Metab Rep"},{"key":"2623_CR76","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.clinbiochem.2020.10.011","volume":"87","author":"C Tang","year":"2021","unstructured":"Tang C, Jia X, Tang F, Liu S, Jiang X, Zhao X, et al. Detection of glucosylsphingosine in dried blood spots for diagnosis of Gaucher disease by LC-MS\/MS. Clin Biochem. 2021;87:79\u201384.","journal-title":"Clin Biochem"},{"issue":"3","key":"2623_CR77","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.3390\/ijms23031627","volume":"23","author":"T Dinur","year":"2022","unstructured":"Dinur T, Bauer P, Beetz C, Kramp G, Cozma C, Iura\u0219cu MI, et al. Gaucher disease diagnosis using Lyso-Gb1 on dry blood spot samples: time to change the paradigm? Int J Mol Sci. 2022;23(3):1627.","journal-title":"Int J Mol Sci"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02623-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02623-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02623-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T17:19:29Z","timestamp":1676308769000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02623-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2623"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02623-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]},"assertion":[{"value":"7 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GG has received consultancy fees from Sanofi Genzyme, UM has received consultancy fees from Sanofi Genzyme and Amgen, MN acted as consultant for Bayer, CSL Behring, Kedrion, Novonordisk and Amgen and received speaker fees from Kedrion, Pfizer, CSLBehring CSL Behring, Novonordisk, Bayer Sobi, and Takeda. JG is an employee of Sanofi Genzyme. Other authors declare they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}